Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics
- PMID: 2555512
- DOI: 10.1021/jm00132a010
Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics
Abstract
Utilizing results from previous structure-activity relationships and theoretical studies of alpha-melanotropin (alpha-MSH, Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) and its related superpotent analogues, Ac-[Nle4,D-Phe7]-alpha-MSH and Ac-[Cys4,Cys10]-alpha-MSH, we have designed a new class of alpha-MSH4-13 and alpha-MSH4-10 cyclic lactam fragment analogues of alpha-melanotropin. The cyclic peptides have the following general structures: Ac-[Nle4,Xxx5,D-Phe7,Yyy10,Gly11]-alpha-MSH4-13- NH2 and Ac-[Nle4,Xxx5,D-Phe7,Yyy10]-alpha-MSH4-10-NH2, where Xxx = Glu or Asp and Yyy = Lys, Orn, Dab, or Dpr. Formation of the lactam bridge between the side-chain groups Xxx and Yyy was performed either in solution or on a solid-phase support. Seven cyclic peptides were prepared and bioassayed for their melanotropic potency by using standard frog (Rana pipiens) and lizard (Anolis carolinensis) skin bioassays. Relative to alpha-MSH (relative potency = 1), the potencies of the cyclic peptides in the lizard skin bioassay were as follows: alpha-MSH (1); Ac-[Nle4,Glu5,D-Phe7,Lys10,Gly11]-alpha-MSH4-13- NH2 (6); Ac-[Nle4,Asp5,D-Phe7,Lys10,Gly11]-alpha-MSH4-13- NH2 (100); Ac-[Nle4,Glu5,D-Phe7,Lys10]-alpha-MSH4-10-NH2 (9); Ac-[Nle4,Asp5,D-Phe7,Lys10]-alpha-MSH4-10-NH2 (90); Ac-[Nle4,Asp5,D-Phe7,Orn10]-alpha-MSH4-10-NH2 (20); Ac-[Nle4,Asp5,D-Phe7,Dab10]-alpha-MSH4-10-NH2 (5); Ac-[Nle4,Asp5,D-Phe7,Dpr10]-alpha-MSH4-10-NH2 (5). Similar results were obtained in the frog skin bioassay, but the analogues were much less potent. Cyclic melanotropins with 23-membered rings exhibited 100-fold higher melanotropic potency than alpha-MSH with selectivity for the lizard melanocyte receptors over the frog melanocyte receptors. Increasing or decreasing the ring size of these cyclic melanotropins from 23 diminishes the biological potency of the resulting cyclic peptide. The 23- and 24-membered ring analogues showed prolonged (residual) biological activities in both biological assays, but the smaller ring systems (20, 21, 22) did not. These results provide new insights into the structural and conformational requirements of alpha-MSH and its analogues at two different types of pigment cell (melanocyte) receptors.
Similar articles
-
Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10.J Med Chem. 1989 Jan;32(1):174-9. doi: 10.1021/jm00121a032. J Med Chem. 1989. PMID: 2535874
-
Cyclic lactam analogues of Ac-[Nle4]alpha-MSH4-11-NH2.Biochemistry. 1988 Oct 18;27(21):8181-8. doi: 10.1021/bi00421a029. Biochemistry. 1988. PMID: 2852955
-
Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors.J Med Chem. 1995 Sep 1;38(18):3454-61. doi: 10.1021/jm00018a005. J Med Chem. 1995. PMID: 7658432
-
[NIe4,Asp5,d-Phe7, 67Ga/68Ga-1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-1,4,7,10-tetraacetic acid-Lys11]-α-MSH4-11.2007 Jul 30 [updated 2007 Nov 19]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Jul 30 [updated 2007 Nov 19]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641555 Free Books & Documents. Review.
-
[18F]FB-(Ac-NIe-Asp-His-d-Phe-Arg-Trp-Gly-Lys-NH2).2007 Aug 2 [updated 2007 Aug 10]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Aug 2 [updated 2007 Aug 10]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641724 Free Books & Documents. Review.
Cited by
-
Molecular Imaging and Radionuclide Therapy of Melanoma Targeting the Melanocortin 1 Receptor.Mol Imaging. 2017 Jan-Dec;16:1536012117737919. doi: 10.1177/1536012117737919. Mol Imaging. 2017. PMID: 29182034 Free PMC article. Review.
-
Beta-turn secondary structure and melanocortin ligands.Bioorg Med Chem. 2009 Feb 1;17(3):952-8. doi: 10.1016/j.bmc.2008.02.090. Epub 2008 Mar 4. Bioorg Med Chem. 2009. PMID: 18343128 Free PMC article.
-
Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist.Biochemistry. 2010 Jun 8;49(22):4583-600. doi: 10.1021/bi100068u. Biochemistry. 2010. PMID: 20462274 Free PMC article.
-
Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity.JCI Insight. 2021 Feb 22;6(4):e132778. doi: 10.1172/jci.insight.132778. JCI Insight. 2021. PMID: 33434184 Free PMC article.
-
The melanocortin circuit in obese and lean strains of chicks.J Endocrinol. 2006 Aug;190(2):527-35. doi: 10.1677/joe.1.06783. J Endocrinol. 2006. PMID: 16899585 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous